• Happy Holidays from AcceGen! Orders placed during Dec 22–Jan 2 will be processed and shipped after operations resume. Please plan ahead.

Tumor Cell Lines

DMS 454

  • For research use only

Cat No.

ABC-TC0215

Product Type

Human Lung Cancer Cell Lines

Species

Human

Growth Conditions

37 ℃, 5% CO2

Source Organ

Lung

Disease

Lung Small Cell Cancer

Product Code

DMS-454; DMS454

Research DMS 454, Human small cell lung carcinoma from a Caucasian male, isolated in 1981, suitable for cancer biology and drug discovery research.

Product Image

Description

DMS-454
DMS-454 is a human small cell lung carcinoma (SCLC) cell line established from the lung tissue of a Caucasian male patient during autopsy. It displays polygonal morphology with adherent growth characteristics and contains dense-core vesicles, secreting calcitonin, indicating neuroendocrine features common to SCLC. The cells can be cultured in Waymouth’s MB 752/1 medium supplemented with 2mM glutamine and 10% fetal bovine serum (FBS), or alternatively in RPMI 1640 with 10% FBS [1]. Routine subculture involves digestion with 0.25% trypsin or trypsin/EDTA and a 1:3 split ratio when cultures reach sub-confluence. Cytogenetic analysis has not been extensively reported, and specific gene mutations remain undefined. However, DMS-454 shares key biological behaviors with other SCLC lines, including likely tumorigenicity and high metastatic potential based on the aggressive nature of its tumor origin. It is suitable for studies on neuroendocrine tumor biology and calcitonin-secreting carcinomas.
Product Code

DMS-454; DMS454

Species

Human

Cat.No

ABC-TC0215

Product Category Tumor Cell Lines
Size/Quantity

1 vial

Growth Mode

Adherent

Shipping Info

Dry Ice

Growth Conditions

37 ℃, 5% CO2

Source Organ

Lung

Disease

Lung Small Cell Cancer

Biosafety Level

1

Storage

Liquid Nitrogen

Product Type

Human Lung Cancer Cell Lines

Application

  • DMS-454 is a valuable model for studying small-cell lung cancer and developing new therapies for these patients. For example, the utilization of DMS-454 provides an opportunity to identify the tumor markers specific to small cell lung cancer (SCLC) in the initial stage. Once these markers are identified, the next step involves assessing the effectiveness of antibodies targeting these markers within the context of CAR-T cell therapy. This approach aims to determine whether the antibodies can effectively engage the markers and initiate the desired immune response to eliminate cancer cells.

Citation

When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).

Inquiring DMS 454

We know how valuable your research is to you, but are you wondering what you can expect to pay for quick accurate results every time? Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
High Viability
To succeed in cell culture
Precision and Reliability
To support a consistent result
Customization Options
Tailed to your research

Tags

AcceGen Scroll Top Button